Pioglitazone-Based Combination Approaches for Non-Small-Cell Lung Cancer.

Pharmaceutics · 2025 · PMC12655413 · PMID 41304753

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The results showed that TZD use was associated with a 33% reduction in lung cancer risk (relative risk 0.67; 95% CI, 0.51–0.87), whereas the reductions in colorectal and prostate cancer risk did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.